{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T10:48:29Z","timestamp":1782730109197,"version":"3.54.5"},"reference-count":35,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"unspecified","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020103","name":"Indiana University Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020103","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,4,17]]},"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To estimate the relative effectiveness of vaccination (0, 1, 2, \u22653 doses) and prior infection, in combination, on risk of SARS-CoV-2 infection\/reinfection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Prospective cohort study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>We recruited participants for the Aegis Study from nine clinics across five US states. Participants must have been 18 years or older, had a history of a positive PCR for SARS-CoV-2, SARS-CoV-2 antigen or antibody test for SARS-CoV-2 with documentation or had no suspected or documented prior SARS-CoV-2 infection, intended to remain in study area for the next 12 months, and had elevated risk of future SARS-CoV-2 exposure. Exclusion criteria included acute illness, contraindication to phlebotomy, use of immunosuppressants or receipt of systemic immunoglobulins.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We used extended Cox regression with robust standard errors to estimate the association between time-varying number of vaccine doses and baseline prior infection on risk of infection\/reinfection among a prospective cohort of US adults between February 2021 and January 2023, accounting for censoring using inverse probability of censoring weights. Additionally, to quantify possible exposure misclassification of prior infection by comparing prior infection operationalised as (1) documented\/self-reported prior infection and (2) documented\/self-reported prior infection plus nucleocapsid antibody indication of prior infection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of n=2178\u2009who completed enrolment, n=1887 adults (63% female; 65% non-Latino White) contributed 366\u2009905\u2009days of observation. Participants contributed an average of 7.2 months of follow-up between February 2021 and January 2023. 28% (n=533) of individuals were infected or reinfected during the study period. Similar relative effectiveness was observed between the two different operationalisations of prior infection. After correction for prior infection status in the nearly 16% of those without study documentation of prior infection who had nucleocapsid antibody levels comparable to documented cases, relative to the unvaccinated with no prior infection, estimated effectiveness generally increased with increasing vaccine doses and prior infection (without prior infection: one (17%, 95%\u2009CI \u221231% to 47%), two (49%, 95%\u2009CI 31% to 63%), \u2265three (71%, 95%\u2009CI 58% to 80%) vaccine doses; with prior infection: none (56%, 95%\u2009CI 30% to 72%), one (71%, 95%\u2009CI 42% to 86%), two (65%, 95%\u2009CI 49% to 76%), \u2265three (80%, 95%\u2009CI 68% to 88%) vaccine doses). Pairwise comparisons at each vaccine dose (ref: no prior infection) revealed that prior infection provided additional protection, with stronger relationships for no and one dose (none: 56% (95% CI 30% to 72%), one: 66% (95% CI 28% to 84%), two: 31% (95% CI 7% to 49%), \u2265three 31% (95% CI 0% to 53%)). There was a marked decrease in the protection offered by vaccination, prior infection, or both in the Omicron period versus pre-Omicron period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In our real-world observational sample, vaccination (with two and \u2265three vaccine doses of any Food and Drug Administration Emergency Use Authorization approved vaccine) and prior infection conferred benefits for protection against infection\/reinfection. Re-classification of prior infection status based on antibody levels had little effect on results.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-112893","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T05:54:46Z","timestamp":1778651686000},"page":"e112893","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["How does prior infection and vaccination relate to the risk of incident SARS-CoV-2 infection\/reinfection? A prospective cohort study among nine clinical sites in the USA, February 2021 to January 2023"],"prefix":"10.1136","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4501-9744","authenticated-orcid":false,"given":"Ashley","family":"Judge","sequence":"first","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Indiana University Bloomington School of Public Health, Bloomington, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika T","family":"Beidelman","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Indiana University Bloomington School of Public Health, Bloomington, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B","family":"Allison","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Indiana University Bloomington School of Public Health, Bloomington, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Dickinson","sequence":"additional","affiliation":[{"name":"Biostatistics Consulting Center, Indiana University Bloomington School of Public Health, Bloomington, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kishore M","family":"Gadde","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of California Irvine School of Medicine, Irvine, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilian","family":"Golzarri Arroyo","sequence":"additional","affiliation":[{"name":"Biostatistics Consulting Center, Indiana University Bloomington School of Public Health, Bloomington, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3118-6859","authenticated-orcid":false,"given":"John P","family":"Ioannidis","sequence":"additional","affiliation":[{"name":"Department of Medicine, Stanford University School of Medicine, Stanford, California, USA"},{"name":"Department of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna LM","family":"Macagno","sequence":"additional","affiliation":[{"name":"Biostatistics Consulting Center, Indiana University Bloomington School of Public Health, Bloomington, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan T","family":"Macy","sequence":"additional","affiliation":[{"name":"Department of Applied Health Science, Indiana University Bloomington School of Public Health, Bloomington, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin C","family":"Maki","sequence":"additional","affiliation":[{"name":"Department of Applied Health Science, Indiana University Bloomington School of Public Health, Bloomington, Indiana, USA"},{"name":"Midwest Biomedical Research Addison, Addison, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley","family":"Perlman","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, University of Iowa, Iowa City, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J","family":"Ricciardi","sequence":"additional","affiliation":[{"name":"Mabloc LLC, Washington, District of Columbia, USA"},{"name":"Department of Pathology, The George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"Rosenberg","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Indiana University Bloomington School of Public Health, Bloomington, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Ludema","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Indiana University Bloomington School of Public Health, Bloomington, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"key":"2026062608323484000_16.5.e112893.1","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2024.1353415","article-title":"Protective effectiveness of previous infection against subsequent SARS-Cov-2 infection: systematic review and meta-analysis","volume":"12","author":"Hu","year":"2024","journal-title":"Front Public Health"},{"key":"2026062608323484000_16.5.e112893.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02465-5"},{"key":"2026062608323484000_16.5.e112893.3","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-50335-6","article-title":"Impact on the time elapsed since SARS-CoV-2 infection, vaccination history, and number of doses, on protection against reinfection","volume":"14","author":"S\u00e1nchez-de Prada","year":"2024","journal-title":"Sci Rep"},{"key":"2026062608323484000_16.5.e112893.4","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(22)00801-5"},{"key":"2026062608323484000_16.5.e112893.5","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104734","article-title":"Effects of previous infection, vaccination, and hybrid immunity against symptomatic Alpha, Beta, and Delta SARS-CoV-2 infections: an observational study","volume":"95","author":"Altarawneh","year":"2023","journal-title":"EBioMedicine"},{"key":"2026062608323484000_16.5.e112893.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2203965"},{"key":"2026062608323484000_16.5.e112893.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2118691"},{"key":"2026062608323484000_16.5.e112893.8","doi-asserted-by":"crossref","first-page":"2200494","DOI":"10.2807\/1560-7917.ES.2023.28.13.2200494","article-title":"Risk of SARS-CoV-2 reinfection by vaccination status, predominant variant and time from prior infection: a cohort study, Reggio Emilia province, Italy, February 2020 to February 2022","volume":"28","author":"Vicentini","year":"2023","journal-title":"Euro Surveill"},{"key":"2026062608323484000_16.5.e112893.9","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa2207082","article-title":"Protection against Omicron from Vaccination and Previous Infection in a Prison System","volume":"387","author":"Chin","year":"2022","journal-title":"N Engl J Med"},{"key":"2026062608323484000_16.5.e112893.10","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.36670","article-title":"Estimated Protection of Prior SARS-CoV-2 Infection Against Reinfection With the Omicron Variant Among Messenger RNA-Vaccinated and Nonvaccinated Individuals in Quebec, Canada","volume":"5","author":"Carazo","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2026062608323484000_16.5.e112893.11","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01796-23","article-title":"Distinguishing SARS-CoV-2 infection and vaccine responses up to 18 months post-infection using nucleocapsid protein and receptor-binding domain antibodies","volume":"11","author":"Jarlhelt","year":"2023","journal-title":"Microbiol Spectr"},{"key":"2026062608323484000_16.5.e112893.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2020.06.024"},{"key":"2026062608323484000_16.5.e112893.13","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0897-1"},{"key":"2026062608323484000_16.5.e112893.14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003061","article-title":"Influenza infection rates, measurement errors and the interpretation of paired serology","volume":"8","author":"Cauchemez","year":"2012","journal-title":"PLoS Pathog"},{"key":"2026062608323484000_16.5.e112893.15","doi-asserted-by":"crossref","DOI":"10.1038\/s43856-025-00894-8","article-title":"Serum anti-nucleocapsid antibody correlates of protection from SARS-CoV-2 re-infection regardless of symptoms or immune history","volume":"5","author":"Miyamoto","year":"2025","journal-title":"Commun Med (Lond)"},{"key":"2026062608323484000_16.5.e112893.16","doi-asserted-by":"crossref","first-page":"127593","DOI":"10.1016\/j.vaccine.2025.127593","article-title":"From first infection to reinfection: Comparing Nucleocapsid antibody kinetics in vaccinated and unvaccinated adults","volume":"62","author":"Lindsey","year":"2025","journal-title":"Vaccine (Auckl)"},{"key":"2026062608323484000_16.5.e112893.17","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2021.770985","article-title":"COVID-19 Vaccine Hesitancy in the United States: A Systematic Review","volume":"9","author":"Yasmin","year":"2021","journal-title":"Front Public Health"},{"key":"2026062608323484000_16.5.e112893.18","doi-asserted-by":"publisher","DOI":"10.1177\/014662167700100306"},{"key":"2026062608323484000_16.5.e112893.19","unstructured":"Rubin DB . Multiple imputation, in flexible imputation of missing data. Chapman and Hall\/CRC, 2018: 29\u201362."},{"key":"2026062608323484000_16.5.e112893.20","unstructured":"Posit Team . RStudio: integrated development environment for R. Posit Software; 2024. Available: http:\/\/www.posit.co\/"},{"key":"2026062608323484000_16.5.e112893.21","unstructured":"Therneau T . A package for survival analysis in R. 2024."},{"key":"2026062608323484000_16.5.e112893.22","doi-asserted-by":"crossref","unstructured":"Therneau TM , Grambsch PM . Modeling survival data: extending the Cox model. Springer, 2000.","DOI":"10.1007\/978-1-4757-3294-8"},{"key":"2026062608323484000_16.5.e112893.23","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v045.i05"},{"key":"2026062608323484000_16.5.e112893.24","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v043.i10"},{"key":"2026062608323484000_16.5.e112893.25","doi-asserted-by":"crossref","unstructured":"Beidelman ET , Judge A , Allison DB , et al . The relationship between psychological stress and SARS-CoV-2 nucleocapsid-antibody response following natural infection: Longitudinal findings from the Aegis Study. Am J Epidemiol 2026.:kwag048. doi:10.1093\/aje\/kwag048","DOI":"10.1093\/aje\/kwag048"},{"key":"2026062608323484000_16.5.e112893.26","doi-asserted-by":"crossref","DOI":"10.1017\/S095026882500010X","article-title":"Using SARS-CoV-2 nucleoprotein antibodies to detect (re)infection","volume":"153","author":"Hoeve","year":"2025","journal-title":"Epidemiol Infect"},{"key":"2026062608323484000_16.5.e112893.27","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1080\/23744235.2025.2479139","article-title":"Anti-SARS-CoV-2 nucleocapsid antibodies to detect exposure to SARS-CoV-2: results from a prospective cohort study on COVID-19 vaccination","volume":"57","author":"Rasmussen","year":"2025","journal-title":"Infect Dis (Lond)"},{"key":"2026062608323484000_16.5.e112893.28","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-31838-8","article-title":"Protection of COVID-19 vaccination and previous infection against Omicron BA.1, BA.2 and Delta SARS-CoV-2 infections","volume":"13","author":"Andeweg","year":"2022","journal-title":"Nat Commun"},{"key":"2026062608323484000_16.5.e112893.29","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00409-1"},{"key":"2026062608323484000_16.5.e112893.30","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(22)00152-0"},{"key":"2026062608323484000_16.5.e112893.31","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)00675-9"},{"key":"2026062608323484000_16.5.e112893.32","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1001\/jamainternmed.2021.0366","article-title":"Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future Infection","volume":"181","author":"Harvey","year":"2021","journal-title":"JAMA Intern Med"},{"key":"2026062608323484000_16.5.e112893.33","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac677","article-title":"Reconsideration of Antinucleocapsid IgG Antibody as a Marker of SARS-CoV-2 Infection Postvaccination for Mild COVID-19 Patients","volume":"10","author":"Dhakal","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2026062608323484000_16.5.e112893.34","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(96)00009-1"},{"key":"2026062608323484000_16.5.e112893.35","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2018.304337"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-112893","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T10:32:55Z","timestamp":1782729175000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-112893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":35,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,12]]},"published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1136\/bmjopen-2025-112893"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-112893","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]}}}